Impact of posaconazole and diltiazem on pharmacokinetics of encorafenib, a BRAF V600 kinase inhibitor for melanoma and colorectal cancer with BRAF mutations

• मुख्य लेखकों: Erik Hahn (लेखक), Renae Chavira (लेखक), Lance Wollenberg (लेखक), Weiwei Tan (लेखक), Micaela B. Reddy (लेखक)
• स्वरूप: पुस्तक
• प्रकाशित: Wiley, 2023-12-01T00:00:00Z.
• विषय: article
• ऑनलाइन पहुंच: Connect to this object online.

Abstract Encorafenib is a potent and selective ATP competitive inhibitor of BRAF V600-mutant kinase approved for patients with BRAF‐mutant melanoma and colorectal cancer. Encorafenib is mainly metabolized by cytochrome P450 (CYP) 3A4 in vitro and may be susceptible to drug-drug interactions when co‐...